Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC

S. Kilickap,A. Sezer,M. Gumus,I. Bondarenko,M. Ozguroglu,M. Gogishvili,H. M. Turk,I. Cicin,D. Bentsion,O. Gladkov,P. Clingan,V. Sriuranpong,N. Rizvi,S. Li,S. Lee,T. Makharadze,S. Paydas,M. Nechaeva,F. Seebach,D. M. Weinreich,G. D. Yancopoulos,G. Gullo,I. Lowy,P. Rietschel

JOURNAL OF THORACIC ONCOLOGY（2021）

引用 1|浏览10
暂无评分
关键词
non-small cell lung cancer,anti-PD-1,cemiplimab
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要